Amgen is trying a new tool to blunt some of the shareholder outrage over executive compensation: a survey.
Tucked away on page 51 of the pharmaceutical giant’s proxy statement is mention of a page on Amgen’s website where shareholders can fill out a 10-question survey asking what they think of the company’s compensation policies. We at Compliance Week haven’t seen something like that before, and we doubt it will placate shareholders all that much—but it’s a gesture, and a much more conciliatory one than the gesture shareholders are giving corporations these days.
